We are live on ! Find out more
VTRS icon

Viatris

502 hedge funds and large institutions have $11.8B invested in Viatris in 2018 Q4 according to their latest regulatory filings, with 87 funds opening new positions, 161 increasing their positions, 187 reducing their positions, and 88 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more call options, than puts

Call options by funds: $166M | Put options by funds: $166M

0.05% less ownership

Funds ownership: 83.77%83.72% (-0.05%)

1% less first-time investments, than exits

New positions opened: 87 | Existing positions closed: 88

2% less funds holding

Funds holding: 511502 (-9)

14% less repeat investments, than reductions

Existing positions increased: 161 | Existing positions reduced: 187

24% less funds holding in top 10

Funds holding in top 10: 1713 (-4)

26% less capital invested

Capital invested by funds: $15.8B → $11.8B (-$4.05B)

Holders
502
Holders Change
-9
Holders Change %
-1.76%
% of All Funds
11.19%
Holding in Top 10
13
Holding in Top 10 Change
-4
Holding in Top 10 Change %
-23.53%
% of All Funds
0.29%
New
87
Increased
161
Reduced
187
Closed
88
Calls
$166M
Puts
$166M
Net Calls
+$190K
Net Calls Change
+$146M
Name Holding Trade Value Shares
Change
Change in
Stake
Mitsubishi UFJ Asset Management
226
Mitsubishi UFJ Asset Management
Japan
$1.78M -$110K -3,408 -5%
AB
227
Amalgamated Bank
New York
$1.74M -$46.5K -1,434 -2%
SIP
228
Stoneridge Investment Partners
Pennsylvania
$1.73M -$729K -22,490 -26%
PA
229
Profund Advisors
Maryland
$1.73M -$424K -13,096 -17%
XK
230
Xact Kapitalforvaltning
Sweden
$1.72M -$855K -26,400 -30%
CA
231
Continental Advisors
Utah
$1.7M +$2.01M +62,100 New
Capital Fund Management (CFM)
232
Capital Fund Management (CFM)
France
$1.66M +$1.96M +60,398 New
Connor, Clark & Lunn Investment Management (CC&L)
233
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
$1.62M +$1.92M +59,180 New
Rafferty Asset Management
234
Rafferty Asset Management
New York
$1.61M +$166K +5,129 +10%
Natixis Advisors
235
Natixis Advisors
Massachusetts
$1.61M -$723K -22,313 -28%
SGH
236
Sivik Global Healthcare
Connecticut
$1.54M -$1.26M -38,814 -41%
OA
237
Oak Associates
Ohio
$1.54M +$690K +21,300 +61%
IA
238
Icon Advisers
Colorado
$1.53M +$1.36M +42,000 +300%
EP
239
Eversept Partners
New York
$1.51M +$1.78M +55,000 New
CIBC Asset Management
240
CIBC Asset Management
Ontario, Canada
$1.5M +$34K +1,049 +2%
TRSOTSOK
241
Teachers Retirement System of the State of Kentucky
Kentucky
$1.48M +$126K +3,900 +8%
SAM
242
Securian Asset Management
Minnesota
$1.43M +$2.56K +79 +0.2%
RIM
243
Regent Investment Management
Kentucky
$1.43M -$1.15M -35,605 -41%
Simplex Trading
244
Simplex Trading
Illinois
$1.39M -$26.1K -805 -2%
B
245
Barings
North Carolina
$1.38M -$445K -13,743 -21%
PCM
246
Palouse Capital Management
Washington
$1.36M -$133K -4,090 -8%
WCM
247
Washington Capital Management
Washington
$1.36M +$138K +4,250 +9%
Los Angeles Capital Management
248
Los Angeles Capital Management
California
$1.35M +$1.6M +49,388 New
HSBC Holdings
249
HSBC Holdings
United Kingdom
$1.35M -$2.65M -81,704 -62%
QOP
250
Quinn Opportunity Partners
Virginia
$1.33M -$130K -4,000 -8%

VTRS Hedge Fund Activity: Q4 2018 in Review

502 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in Viatris (VTRS) for Q4 2018, worth a combined $11.8B — down 26% from $15.8B a quarter earlier.

Sellers outnumbered buyers: 88 funds closed out of VTRS and 87 opened new positions — a net loss of 1 holder — while 187 trimmed existing stakes and 161 added.

The largest buyer was Goldman Sachs, adding an estimated $126M. The largest seller was PFM Health Sciences, exiting entirely with an estimated $172M sold.

  • 502 institutional investors held Viatris (VTRS) as of Q4 2018, down from 511 in Q3 2018.
  • Funds reported $11.8B of Viatris stock for Q4 2018, down 26% quarter-over-quarter.
  • 87 funds opened new Viatris positions in Q4 2018 and 88 closed out, a net change of -1 holder.
  • The largest Viatris buyer in Q4 2018 was Goldman Sachs, an estimated $126M added.
  • The largest Viatris seller in Q4 2018 was PFM Health Sciences, an estimated $172M sold.

Based on aggregated 13F filings for Q4 2018.